Cargando…
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
BACKGROUND: Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). The identification of a chemotherapeutic regimen that is both effective and tolerable is critical for NAC...
Autores principales: | Alva-Ruiz, Roberto, Yohanathan, Lavanya, Yonkus, Jennifer A., Abdelrahman, Amro M., Gregory, Lindsey A., Halfdanarson, Thorvadur R., Mahipal, Amit, McWilliams, Robert R., Ma, Wen Wee, Hallemeier, Christopher L., Graham, Rondell P., Grotz, Travis E., Smoot, Rory L., Cleary, Sean P., Nagorney, David M., Kendrick, Michael L., Truty, Mark J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810469/ https://www.ncbi.nlm.nih.gov/pubmed/34724125 http://dx.doi.org/10.1245/s10434-021-10991-2 |
Ejemplares similares
-
Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors
por: Gudmundsdottir, Hallbera, et al.
Publicado: (2022) -
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021) -
Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria
por: Anger, Friedrich, et al.
Publicado: (2020) -
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023) -
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)